Skip to main content
. 2014 Sep 27;7:65. doi: 10.1186/s13045-014-0065-5

Figure 2.

Figure 2

Antiplatelets/NSAIDs are inversely associated with survival in HNSCC. A. Intake of these medications confers better outcomes in the general HNSCC patient population, B. The benefit associated with intake of antiplatelets/NSAIDs is particularly observed in the thrombocytosis group, HR = 0.42, p = 0.06. AP: Antiplatelets. ns: Not significant.